Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review

References

• Lieberman P. The basics of histamine biology. Ann Allergy Asthma Immunol 2011;106(Suppl 2):S2-5
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl 5):S147-334
   PubMed Web of Science ®Google Scholar
• Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-98
   PubMed Web of Science ®Google Scholar
• Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010;65:459-66
   PubMed Web of Science ®Google Scholar
• Shimamura T, Shiroishi M, Weyand S, et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 2011;475:65-70
   PubMed Web of Science ®Google Scholar
• Bousquet J, Van Cauwenberge P, Bachert C, et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy 2003;58:192-7
   PubMed Web of Science ®Google Scholar
• Bousquet J, van Cauwenberge P, Ait Khaled N, et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA(2)LEN). Allergy 2006;61:1086-96
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bachert C, Canonica GW, et al. Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy 2009;64:1516-23
   PubMed Web of Science ®Google Scholar
• Bachert C, Bousquet J, Canonica GW, et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838-44
   PubMed Web of Science ®Google Scholar
• Bousquet J, Demarteau N, Mullol J, et al. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 2005;60:788-94
   PubMed Web of Science ®Google Scholar
• Fantin S, Maspero J, Bisbal C, et al. A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy 2008;63:924-31
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bachert C, Canonica GW, et al. Efficacy of desloratadine in persistent allergic rhinitis - a GA(2)LEN study. Int Arch Allergy Immunol 2010;153:395-402
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Tosca MA, Marseglia GL, et al. Relationships between allergic inflammation and nasal airflow in children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005;94:258-61
   PubMed Web of Science ®Google Scholar
• Bousquet J, Annesi-Maesano I, Carat F, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005;35:728-32
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76
   PubMed Web of Science ®Google Scholar
• Brozek JL, Baena-Cagnani CE, Bonini S, et al. Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy 2008;63:38-46
   PubMed Web of Science ®Google Scholar
• Bousquet J, Schunemann HJ, Zuberbier T, et al. Development and implementation of guidelines in allergic rhinitis - an ARIA-GA(2)LEN paper. Allergy 2010;65:1212-21
   PubMed Web of Science ®Google Scholar
• Costa DJ, Bousquet PJ, Ryan D, et al. Guidelines for allergic rhinitis need to be used in primary care. Prim Care Respir J 2009;18:250-7
   PubMedGoogle Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427-43
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006;61:321-31
   PubMed Web of Science ®Google Scholar
• Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf 2011;10:779-93
   PubMed Web of Science ®Google Scholar
• Corcóstegui R, Labeaga L, Innerárity A, et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005;6:371-84
   PubMedGoogle Scholar
• Corcóstegui R, Labeaga L, Innerárity A, et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D 2006;7:219-31
   PubMedGoogle Scholar
• Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158:693-705
   PubMed Web of Science ®Google Scholar
• Franke RM, Scherkenbach LA, Sparreboom A. Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 2009;10:339-44
   PubMed Web of Science ®Google Scholar
• Seden K, Dickinson L, Khoo S, et al. Grapefruit-drug interactions. Drugs 2010;70:2373-407
   PubMed Web of Science ®Google Scholar
• Miura M, Uno T. Clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol 2010;6:69-74
   PubMed Web of Science ®Google Scholar
• Bachert C, Kun P, Zuberbier T. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy 2010;65(Suppl 3):1-13
   Google Scholar
• Hanley M, Cancalon P, Widmer W, Greenblatt D. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 2011;7:267-286
   PubMed Web of Science ®Google Scholar
• BILAXTEN® 20 mg coated tablets. Bilastine 20 mg. FAES FARMA S.A. Authorized Summary of Product Characteristics. http://www.medicinesorguk/emc/medicine/24461/SPC/ilaxten%2020%20mg%20tablets/. Text updated: November 2010. Accessed September 21, 2011
   Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010;59:391-8
   PubMed Web of Science ®Google Scholar
• Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs. desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64:158-65
   PubMed Web of Science ®Google Scholar
• Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009;39:1338-47
   PubMed Web of Science ®Google Scholar
• Sastre JN, Mullol J, Valero A, et al. on behalf of Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2011 Nov 13. [Epub ahead of print]
   Google Scholar
• Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs. levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010;65:516-28
   PubMed Web of Science ®Google Scholar
• Garcia-Gea C, Martinez-Colomer J, Antonijoan RM, et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008;28:675-85
   PubMed Web of Science ®Google Scholar
• Conen S, Theunissen EL, Van Oers AC, et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2010 Sep 20. [Epub ahead of print]
   Google Scholar
• Wolf S, Brubcker K, Navrail T, et al. Evaluation of muscarinic receptor antagonism by antihistamines. XXVI Congress of the European Academy of Allergology and Clinical Immunology. Göteborg (Sweden) Jun. 9-13, 2007. Allergy 2007;62 (Suppl 83):138 [Abstract 365]
   Google Scholar
• Taglialatela M, Castaldo P, Pannaccione A, et al. Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin Exp Allergy 1999;3:182-9
   Web of Science ®Google Scholar
• Tyl B, Kabbaj M, Azzam S, et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a Thorough QT Study (TQTS) with QT-concentration analysis. J Clin Pharmacol 2011 Jun 3.[Epub ahead of print] [DOI:10.1177/0091270011407191]
   Google Scholar
• Jauregizar N, de la Fuente L, Lucero ML, et al. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet 2009;48:543-54
   PubMed Web of Science ®Google Scholar
• Sadaba Díaz de Rada B, Azanza Perea JR, Gómez-Guiu Hormigos A. Bilastine for the relief of allergy symptoms. Drugs Today (Barc) 2011;47:251-62
   PubMed Web of Science ®Google Scholar
• Baiardini I, Bousquet PJ, Brzoza Z, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy 2010;65:290-5
   PubMed Web of Science ®Google Scholar
• Baiardini I, Braido F, Tarantini F, et al. ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA(2)LEN review. Allergy 2008;63:660-9
   PubMed Web of Science ®Google Scholar